TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis

Blood

Volumn 124, Issue 2, 2014, Pages 251-258

  Stengel, Anna ^a   Schnittger, Susanne ^a   Weissmann, Sandra ^a   Kuznia, Sabrina ^a   Kern, Wolfgang ^a   Kohlmann, Alexander ^a   Haferlach, Torsten ^a   Haferlach, Claudia ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CHROMOSOME NUMBER; CORRELATIONAL STUDY; CYTOGENETICS; FEMALE; GENE DELETION; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HYPODIPLOID; IMMUNOPHENOTYPING; INFANT; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; ONCOGENE MYC; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRE B LYMPHOCYTE; PRE T LYMPHOCYTE; PRIORITY JOURNAL; WILD TYPE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; GENE FREQUENCY; GENES, MYC; HUMANS; INFANT; MALE; MIDDLE AGED; MUTATION; PLOIDIES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84904099284     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-558833     Document Type: Article

References (45)

1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030-1043. (Pubitemid 351389536)
2. Chiaretti S, Brugnoletti F, Tavolaro S, et al. TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy. Haematologica. 2013;98(5):e59-e61.
3. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339(9):605-615. (Pubitemid 28385659)
4. Mullighan CG. The molecular genetic makeup of acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program). 2012;2012:389-396.
5. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278(5340):1059-1064. (Pubitemid 27517875)
6. Agirre X, Novo FJ, Calasanz MJ, et al. TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia. Mol Carcinog. 2003;38(4):201-208. (Pubitemid 37523712)
7. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer. 1994;57(1):1-9. (Pubitemid 24117091)
8. Wickremasinghe RG, Prentice AG, Steele AJ. p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies. Leukemia. 2011;25(9):1400-1407.
9. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358(6381):15-16.
10. Fenaux P, Preudhomme C, Quiquandon I, et al. Mutations of the P53 gene in acute myeloid leukaemia. Br J Haematol. 1992;80(2):178-183.
11. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473-4479.
12. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer. 2011;2(4):466-474.
13. Preudhomme C, Fenaux P. The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies. Br J Haematol. 1997;98(3):502-511. (Pubitemid 27386527)
14. Agirre X, Vizmanos JL, Calasanz MJ, García-Delgado M, Larráyoz MJ, Novo FJ. Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients. Oncogene. 2003;22(7):1070-1072. (Pubitemid 36313150)
15. Clore GM, Ernst J, Clubb R, et al. Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nat Struct Biol. 1995;2(4):321-333.
16. Rotter V, Aloni-Grinstein R, Schwartz D, et al. Does wild-type p53 play a role in normal cell differentiation? Semin Cancer Biol. 1994;5(3):229-236. (Pubitemid 124006733)
17. Wynford-Thomas D. Cellular senescence and cancer. J Pathol. 1999;187(1):100-111. (Pubitemid 29009840)
18. Shaw P, Freeman J, Bovey R, Iggo R. Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene. 1996;12(4):921-930. (Pubitemid 26072278)
19. Sakaguchi K, Herrera JE, Saito S, et al. DNA damage activates p53 through a phosphorylationacetylation cascade. Genes Dev. 1998;12(18):2831-2841. (Pubitemid 28440142)
20. Kruse JP, Gu W. Modes of p53 regulation. Cell. 2009;137(4):609-622.
21. Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1994;22(17):3551-3555. (Pubitemid 24299821)
22. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer. 2001;1(1):68-76. (Pubitemid 33741882)
23. Hof J, Krentz S, van Schewick C, et al. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol. 2011;29(23):3185-3193.
24. Wada M, Bartram CR, Nakamura H, et al. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood. 1993;82(10):3163-3169. (Pubitemid 23334946)
25. Tang JL, Tien HF, Lin MT, Chen PJ, Chen YC. Frequent p53 mutation in relapsed acute lymphoblastic leukemia with cytogenetic instability: a longitudinal analysis. Anticancer Res. 1998;18(2B):1273-1278.
26. Zhu YM, Foroni L, McQuaker IG, Papaioannou M, Haynes A, Russell HH. Mechanisms of relapse in acute leukaemia: involvement of p53 mutated subclones in disease progression in acute lymphoblastic leukaemia. Br J Cancer. 1999;79(7-8):1151-1157. (Pubitemid 29087889)
27. Mühlbacher V, Zenger M, Schnittger S, et al. Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%. Genes Chromosomes Cancer. 2014;53(6):524-536.
28. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood. 2004;104(10):3078-3085. (Pubitemid 39517010)
29. Bene MC, Castoldi G, Knapp W, et al European Group for the Immunological Characterization of Leukemias (EGIL). Proposals for the immunological classification of acute leukemias. Leukemia. 1995;9(10):1783-1786.
30. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lympoid Tissues. Lyon, France: IARC; 2008.
31. Schoch C, Haferlach T. Cytogenetics in acute myeloid leukemia. Curr Oncol Rep. 2002;4(5):390-397.
32. Shaffer LG, Tommerup N. ISCN 2013: An International System for Human Cytogenetic Nomenclature. Basel, New York: Karger; 2013.
33. Grossmann V, Roller A, Klein HU, et al. Robustness of amplicon deep sequencing underlines its utility in clinical applications. J Mol Diagn. 2013;15(4):473-484.
34. Grossmann V, Kohlmann A, Zenger M, et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia. 2011;25(3):557-560.
35. Kocialkowski S, Pezzella F, Morrison H, et al. Mutations in the p53 gene are not limited to classic 'hot spots' and are not predictive of p53 protein expression in high-grade non-Hodgkin's lymphoma. Br J Haematol. 1995;89(1):55-60.
36. Bellini MF, Cadamuro AC, Succi M, Proença MA, Silva AE. Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol. 2012;2012:891961.
37. Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia. 2008;22(8):1539-1541.
38. Dicker F, Herholz H, Schnittger S, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia. 2009;23(1):117-124.
39. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000;77:81-137. (Pubitemid 29439303)
40. Prokocimer M, Unger R, Rennert HS, Rotter V, Rennert G. Pooled analysis of p53 mutations in hematological malignancies. Hum Mutat. 1998;12(1):4-18. (Pubitemid 28262219)
41. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994;265(5170):346-355. (Pubitemid 24259959)
42. Grossmann V, Schnittger S, Kohlmann A, et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood. 2012;120(15):2963-2972.
43. Holmfeldt L, Wei L, Diaz-Flores E, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45(3):242-252.
44. Fielding AK, Zakout GA. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2013;8(2):98-108.
45. Charrin C, Thomas X, Ffrench M, et al. A report from the LALA-94 and LALA-SA groups on hypodiploidy with 30 to 39 chromosomes and near-triploidy: 2 possible expressions of a sole entity conferring poor prognosis in adult acute lymphoblastic leukemia (ALL). Blood. 2004;104(8):2444-2451. (Pubitemid 39331846)